Viral hepatitis remains a significant global health challenge, with chronic infections of hepatitis B virus (HBV) and hepatitis C virus (HCV) acting as major causes of severe liver complications, including cirrhosis, end-stage liver disease, and liver cancer known as hepatocellular carcinoma (HCC) [1], [8]. While viral hepatitis can affect anyone, medical advancements have transformed how these chronic conditions are managed and treated [8]. Understanding the role of antiviral therapy helps patients and clinicians work together to prevent long-term liver damage.
The Goals of Modern Antiviral Therapy
The primary objectives of treating chronic viral hepatitis focus on halting disease progression and preventing life-threatening liver complications. For hepatitis C, the medical field has achieved remarkable breakthroughs with highly effective, well-tolerated direct-acting antivirals (DAAs) that provide curative regimens [7], [8]. These treatments typically clear the virus from the body, achieving a sustained virologic response.
For chronic hepatitis B, complete elimination of the virus remains difficult because of stable viral reservoirs within liver cells, such as covalently closed circular DNA (cccDNA) [4]. Therefore, the primary goal of hepatitis B therapy is long-term viral suppression using safe and tolerable medications like nucleos(t)ide analogues (such as tenofovir or entecavir) [3], [8]. Newer therapeutic strategies and biomarkers, such as serum HBcrAg, are also helping clinicians better monitor residual viral activity and evaluate deeper functional cures [4]. Additionally, pegylated interferon-alpha is utilized to help clear hepatitis B surface antigens in specific patient populations, which significantly reduces the risk of liver cancer [6].
Preventing Complications and Liver Cancer
Chronic inflammation driven by untreated HBV or HCV can gradually scar the liver, leading to cirrhosis and malignancies. Data tracking older adults demonstrates that managing chronic viral infections is critical for public health [1]. Effective antiviral treatments help stabilize or reduce liver-related complications, lowering the incidence of hepatitis-attributable hepatocellular carcinoma over time [1]. By suppressing viral replication or curing the infection, therapies protect the liver architecture from ongoing immune-mediated destruction.
Managing Complex Patients and Co-Existing Conditions
Treating viral hepatitis requires careful coordination when patients have other underlying health issues, such as inflammatory bowel disease (IBD) [2], [3], [5]. Research shows that the prevalence of HBV and HCV in IBD patients is generally similar to that of the general population [3]. However, managing these intersecting conditions demands specialized care:
- Routine screening for HBV markers is recommended for all IBD patients at the time of their diagnosis [3].
- Patients receiving immunosuppressive medications or anti-TNF drugs face a higher risk of severe liver dysfunction or HBV reactivation unless preventive antiviral therapy is given [3].
- Because interferon treatments can occasionally worsen underlying gastrointestinal inflammation in IBD, preferred protocols favor nucleos(t)ide analogues for managing hepatitis B [3].
- Antiviral therapy for hepatitis C is generally considered safe in individuals with well-controlled IBD, though clinical monitoring remains essential [5].
Overcoming Barriers to Care
Despite the availability of curative options for hepatitis C, public health frameworks note that global and regional eradication goals still face hurdles [7], [8]. Obstacles such as insurance restrictions, social stigmas, and gaps in the care cascade—the step-by-step framework adapted from HIV care involving diagnosis, linkage, and treatment initiation—can delay recovery [7]. Expanding community-based testing, streamlining rapid treatment access, and ensuring widespread education are vital steps to ensure that every eligible patient receives life-saving antiviral therapy [7], [8].
Sources
- 1. Trends in hepatocellular carcinoma and viral hepatitis treatment in older Americans
- 2. Inflammatory bowel disease and hepatitis B and C in Western Balkans: a referral centre study and review of the literature
- 3. Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease
- 4. Predictive value of serum HBcrAg in antiviral therapy for chronic hepatitis B
- 5. Hepatitis C virus and inflammatory bowel disease
- 6. Hepatitis B surface antigen clearance rate with pegylated interferon-α therapy in different chronic hepatitis B virus infection populations: A systematic review and meta-analysis
- 7. Meeting Patients with Hepatitis C Where They Are: Lessons from the HIV Epidemic in the USA
- 8. Therapeutic Advances in Viral Hepatitis A-E